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EARLY MIXED CHIMERISM DOES NOT ALTER LONG-TERM PROGNOSIS
FOR PATIENTS RECEIVING IV BUSULFAN-FLUDARABINE (IV BU-FLU)
WITH ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML/MDS
Tang, X.1, de Lima, M.2, Wei, W.2, Chiattone, A.2, Thall, P.F.3,
Medeiros, L.J.4, Rondon, G.2, Shpall, E.J.2, Jones, R.B.2, Nieto, Y.2,
Alousi, A.2, Champlin, R.E.2, Andersson, B.S.2 1Jiangsu Institute of
Hematology, Soochow, China; 2UT MD Anderson Cancer Center,
Houston, TX; 3UT MD Anderson Cancer Center, Houston, TX; 4UT
MD Anderson Cancer Center, Houston, TX
Achieving a full versus a mixed chimeric state has been associated
with a more favorable outcome after allogeneic stem cell transplan-
tation (allo-SCT) for leukemia.Wewere intrigued by what appeared
to be a high incidence of early (SCT day+30) mixed chimerism, yet
a low incidence of serious toxicity and aGvHD, coupled with excel-
lent overall (OS) and disease-free survival (DFS), especially for pa-
tients transplanted in remission (CR or CRp), when using the
reduced-toxicity IV Bu-Flu regimen described by de Lima et al
(BLOOD 2004;104:857-64). We hypothesized that use of a highly
sensitive PCR-based chimerism assessment technique, as well as sep-
arate assaying of myeloid- and T-cell chimerism, might provide
more reliable data for assessing the prognostic value of chimerism
for overall (OS) and disease-free survival (DFS) after allo-SCT.
Patients and Methods: Chimerism assay was performed with
a PCR-based technique to assess microsatellite polymorphism of in-
formative loci, and multi-variate Cox models including chimerism
and other covariates were fit for OS and DFS (Table 1).
Results: 206 AML/MDS patients received Flu at 40mg/m2 daily for
4 days, each dose followed by IV Bu, either at 130mg/m2 or pharma-
cokinetically targeted to an average daily systemic exposure of 6,000
mMol-min. There were 108 males and 98 females, median age of 47
years (16-66). Sixty-six were in first CR, 48 in second CR, 18 had 1st
refractory relapse, 20 were in 1st or 2nd untreated relapse, 37 had in-
duction failures, and 17 high-risk MDS. One patient died before day
+30 and so did not have chimerism studies. The median follow-up of
patients still alive is 5.5 yrs (range 1.3 - 8.6); 193 patients who en-
grafted and were in CR on day +30 had chimerism analyses; 64%
were full chimeras, 36% were mixed chimeras (i.e. $ 1% host cell
DNA). Achieving CR after SCT was important, as was a cytogenetic
‘‘high-risk’’ subgroup (mainly -5/-7, Ph+, or complex chr. abnormal-
ities). However, in the multivariate model neither higher age nor at-
tainment of full vs. mixed donor chimerism by day +30 were of
additional predictive value for either OS or DFS.
We conclude that when the reduced-toxicity IV Bu-Flu regimen is
used for AML/MDS only cytogenetic subgroup (high-risk/others)
and disease state (CR/No CR) but neither patient age nor chimeric
state by SCT day +30 were independently predictive of an altered
prognosis relative to OS and DFS.
Table 1.
95% HazardParameter b SE(b) P-valueHazard
RatioRatio Confidence
LimitsAge (1 yr increase) 0.002 0.009 0.82 1.00 0.99 1.02D+30 chimerism (yes vs. no) -6.68 4.94 0.18 0.001 0.00 20.32D+30 chimerism (magnitude) 0.064 0.050 0.20 1.07 0.97 1.18Cytog risk (Bad vs. others) 0.42 0.20 0.035 1.52 1.03 2.23Disease status at Tx
(CR/CRp vs. others)-0.89 0.21 <.0001 0.41 0.27 0.61414
SAFETY AND UTILITY OF LIVER BIOPSY IN ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT RECIPIENTS WITH LIVER DYSFUNCTION
Benjamin, H., Costa, R., Tiriveedhi, L., Rossetti, J., Sahovic, E., Lister, J.
Western Pennsylvania Cancer Institute, Pittsburgh, PA
Background: Liver disease is a common, often complex complica-
tion of allogeneic hematopoietic stem cell transplantation (HSCT)
with multi-factorial etiology. Accurate diagnosis is typically made
using a combination of clinical, laboratory and radiological data, as-
sisted by a knowledge of risk factors for particular liver disease.Methods: To evaluate the safety and utility of liver biopsy in this
population, we reviewed data of 45 allogeneicHSCTand donor lym-
phocyte infusion (DLI) recipients who underwent liver biopsy for
hepatic dysfunction of unclear etiology from 1995 to 2006. Seven pa-
tients had the procedure performed more than once, yielding a total
number of 55 studies.
Results: Time to liver biopsy and liver function studies prior to the
procedure were analyzed with patient characteristics depicted in the
table below. As a result of this procedure, graft versus host disease
(GVHD) was confirmed in 23/49 (47%) of suspected cases and sinu-
soidal obstructive syndrome (SOS) was confirmed in 1/3 (33%) of
suspected cases. Similarly, infection and disease relapse were present
in only 33% and 29% of suspected cases, respectively. Drug toxicity,
however, was confirmed in 12/20 (60%) of suspected cases. The pro-
cedure was helpful in modifying or continuing current therapy in
40% of the cases. A total of 13% of the procedures had associated
complications including capsular perforation with fatal hemorrhage
(n 5 2, 4%).
Conclusions: While not without risk, liver biopsy findings con-
firmed or refuted the clinical diagnosis in 60% of cases. This infor-
mation was used tomodify therapy in 40%of cases.Whether the risk
of liver biopsy is justified by the benefit of therapeutic change
remains to be demonstrated by further investigation.
Table 1. Patient CharacteristicsPatients n 5 45






Hodgkin’s Lymphoma 4 (9%)
Non-Hodgkin’s Lymphoma 13 (29%)
MDS 7 (16%)
Multiple Myeloma 1 (2%)ALL indicates Acute Lymphocytic Leukemia, AML: Acute Myelogenous
Leukemia; CML: Chronic Myeloid Leukemia; MDS: Myelodysplastic
Syndrome415
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PA-
TIENTS WITH LIGHT RENAL FAILURE
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Center, Jichi Medical University, Saitama, Japan; 2University of Tokyo,
Tokyo, Japan; 3Kanagawa Cancer Center, Kanagawa, Japan; 4Chiba
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Background: Although renal function may affect the outcome of al-
logeneic hematopoietic stem cell transplantation (HSCT),mildly re-
duced renal function which is defined as serum creatinine level
between 1.2 to 2.0 mg/dl did not correlate with non-relapse mortal-
ity (NRM) in the analysis of hematopoietic cell transplantation co-
morbidity index (HCT-CI). Creatinine clearance rate (Ccr) is
a useful and exact way to asses renal function. Impact of renal func-
tion which is evaluated using Ccr before HSCT on the outcome has
not been investigated yet.
Purpose: The aim of this study is to assess the outcome of patients
with mildly reduced renal function which was defined by Ccr before
HSCT.
Method: Patients who underwent allogeneic HSCT using calci-
neurin inhibiter between January, 2004 and December, 2008 at the
seven institutes of Kanto Study Group for Cell Therapy (KSGCT)
with an available Ccr data before HSCT were included in this study.
